Navigation Links
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Date:12/21/2007

s not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Integrated Safety Data: Safety data from phase 2 and 3 studies of single- agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
2. Synova Healthcare to Participate in Womens Health Care in the New Millennium Conference, as Retail Distribution for the Fem-V(R) Test Kit Expands
3. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
4. 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
5. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
6. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
7. Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. Global Med Technologies(R), Inc. Submits ElDorado Donor(TM) to FDA
10. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
11. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... SWAccessControl.com's high quality access control power ... company has announced its new collection of power suppliers. ... high quality power suppliers. All the new models come ... offer lasts until Dec. 20, 2014. , SWAccessControl.com has ... been supporting it for a long time. It is ...
(Date:11/23/2014)... CA (PRWEB) November 23, 2014 ... American Medical Aesthetics & Wellness was recently featured ... Milgrom, Ph.D. is president and CEO of American Medical ... Dr. Asher Milgrom received a full scholarship to attend ... the Medical School at the University of Chicago, where ...
(Date:11/23/2014)... 2014 Syngenta lawsuits are now being ... farmers and agribusinesses that have allegedly incurred significant financial ... Viptera and Agrisure Duracade, genetically modified (GMO) corn ... sale in China. According to a report from Bloomberg ... U.S. corn imports. Because China is the third-largest American ...
(Date:11/23/2014)... 23, 2014 Today Zane Benefits, ... small businesses, announced their new on demand webinar ... Employer-Provided Health Insurance. , According to ... financial risk facing most American families. It is ... and large, when it comes to recruiting and ...
(Date:11/22/2014)... Raleigh, NC (PRWEB) November 23, 2014 ... have found a connection between intercellular communication tunnels and ... to read the full story on the Surviving ... Cancer Center and the University of Minnesota have just ... that carry information and materials between cells. They found ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2
... or delay the onset of prostate cancer, however, finasteride ... than 18,000 men were randomized , age 55 or ... digital rectal examination results were normal in all subjects, ... 3.0 ng/mL. Among the 4368 men in the finasteride ...
... Researchers have found yet another benefit of taking aspirin. ... or more times a week may lower their risk ... data from more than 28,000 women in the Iowa ... other non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, could ...
... HIV-infected patients turn to complementary and alternative medicine, ... and factors associated with such use. ,In ... 3,000 patients enrolled in the HIV Cost and ... who received conventional HIV care, researchers determined demographic ...
... something, let it out and it might save ... people with headaches internalize their anger more than ... participated in the study, 171 suffered from headaches. ... in daily life), internalized anger, hostility, anxiety and ...
... ,Each year, 200,000 women in the United States are diagnosed ... the vitamin may enhance the effect of radiation treatment for ... alone to mice exposed to both radiation and EB 1089, ... in those women treated //with EB 1089 was 50-percent lower ...
... The latest results from the ongoing Nurses Health Study ... amount of alcohol each day may decrease their risk ... alcohol intake has produced conflicting results, with most studies ... lower risk among light to moderate drinkers. Scientists speculate ...
Cached Medicine News:Health News:,Alternative Therapy in HIV Patients 2
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
(Date:11/21/2014)...  The University of Maryland,s A. James Clark School ... the new A. James Clark Hall at the University ... transformative new engineering and biomedical technologies to accelerate advancements ... a.m. on November 21 at the site of the ... to the Jeong H. Kim Engineering Building, the event ...
(Date:11/21/2014)...  Tandem Diabetes Care ® , Inc. (NASDAQ: ... and manufacturer of the t:slim ® Insulin ... non-profit dedicated to improving diabetes therapy management by ... diabetes data accessibility. This partnership will enable users ... development, to download and access data from their ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
96 well format, Gradient features tests 12 PCR annealing temperatures in 1 run...
... Family offers fast temperature control, exact block ... Personal cards enable safe program storage as ... individual protocols between different Mastercyclers. All models ... come with a two-year warranty. The ...
... with unique High Temperature Range ... available heating and cooling rates ... Pressure Lid for automated sealing ... motorized lid for automated opening/closing ...
... a graphical touch screen display which enables ... "touch of a screen." Features & ... Screen, Graphical Display, Memory Cards, Gradient Calculator, ... Intuitive Programmin, Free Instrument Software Upgrade. ...
Medicine Products: